WO2015143343A3 - Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring - Google Patents
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring Download PDFInfo
- Publication number
- WO2015143343A3 WO2015143343A3 PCT/US2015/021784 US2015021784W WO2015143343A3 WO 2015143343 A3 WO2015143343 A3 WO 2015143343A3 US 2015021784 W US2015021784 W US 2015021784W WO 2015143343 A3 WO2015143343 A3 WO 2015143343A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- treatment
- therapy monitoring
- compositions
- immune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of TIGIT, Flg2 and/or IL-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of autoimmune diseases and/or inflammation (e.g., caused by parasitic infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of asthma, allergy, and/or atopy. Methods for identifying patients who are more likely to be responsive to and benefit from an immunotherapy that targets TIGIT, Fg12 and/or IL-33 are also described herein.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15765469.0A EP3119913B1 (en) | 2014-03-21 | 2015-03-20 | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
US15/127,983 US20170107300A1 (en) | 2014-03-21 | 2015-03-20 | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
US16/149,589 US20190040154A1 (en) | 2014-03-21 | 2018-10-02 | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968835P | 2014-03-21 | 2014-03-21 | |
US61/968,835 | 2014-03-21 | ||
US201461981019P | 2014-04-17 | 2014-04-17 | |
US61/981,019 | 2014-04-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/127,983 A-371-Of-International US20170107300A1 (en) | 2014-03-21 | 2015-03-20 | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
US16/149,589 Division US20190040154A1 (en) | 2014-03-21 | 2018-10-02 | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015143343A2 WO2015143343A2 (en) | 2015-09-24 |
WO2015143343A3 true WO2015143343A3 (en) | 2016-03-24 |
Family
ID=54145484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/021784 WO2015143343A2 (en) | 2014-03-21 | 2015-03-20 | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
Country Status (3)
Country | Link |
---|---|
US (2) | US20170107300A1 (en) |
EP (1) | EP3119913B1 (en) |
WO (1) | WO2015143343A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2019118984A (en) | 2014-01-10 | 2019-08-06 | Анаптисбайо, Инк. | ANTIBODIES AIMED AGAINST INTERLEUKIN-33 (IL-33) |
SG11201703767XA (en) | 2014-11-10 | 2017-06-29 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
WO2016077366A1 (en) | 2014-11-10 | 2016-05-19 | Genentec, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
BR112017013385A2 (en) | 2014-12-23 | 2018-02-06 | Bristol-Myers Squibb Company | antibodies to tigit |
MA41463A (en) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) |
TWI715587B (en) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit-binding agents and uses thereof |
US20190255107A1 (en) * | 2015-10-09 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
KR102461228B1 (en) | 2016-11-30 | 2022-10-31 | 온코메드 파마슈티칼스, 인크. | A method of treating cancer comprising a TIGIT-binding agent |
CN110573174A (en) * | 2017-02-17 | 2019-12-13 | 通用医疗公司 | Methods and compositions for treating brain injury |
TW202402800A (en) | 2017-05-01 | 2024-01-16 | 美商艾吉納斯公司 | Anti-tigit antibodies and methods of use thereof |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
US11325969B2 (en) | 2017-08-29 | 2022-05-10 | Veritas Therapeutics Inc. | FGL2 antibodies and binding fragments thereof and uses thereof |
US11512129B2 (en) | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
EP3710015B1 (en) | 2017-11-15 | 2024-01-17 | Université Laval | Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections |
AU2019271304A1 (en) * | 2018-05-15 | 2020-11-26 | The Council Of The Queensland Institute Of Medical Research | Modulating immune responses |
TW202023625A (en) | 2018-08-23 | 2020-07-01 | 美商西雅圖遺傳學公司 | Anti-tigit antibodies |
US11739156B2 (en) * | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
US20220340660A1 (en) * | 2019-10-01 | 2022-10-27 | Merck Sharp & Dohme Corp. | Biomarkers for anti-tigit antibody treatment |
CN110687289B (en) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Application of FGL2 protein as malaria infection marker |
CN110559437B (en) * | 2019-10-17 | 2023-03-14 | 中国人民解放军陆军军医大学 | Application of anti-FGL 2 antibody in preparation of medicines for treating malaria infection |
US20230037966A1 (en) * | 2020-01-07 | 2023-02-09 | The Trustees Of The University Of Pennsylvania | Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies |
KR20220154140A (en) | 2020-03-13 | 2022-11-21 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | PVRIG binding proteins and their medical uses |
KR20220152262A (en) | 2020-03-13 | 2022-11-15 | 제넨테크, 인크. | Anti-interleukin-33 antibodies and uses thereof |
JP2023531200A (en) | 2020-06-18 | 2023-07-21 | ジェネンテック, インコーポレイテッド | Treatment with anti-TIGIT antibody and PD-1 axis binding antagonist |
TW202216778A (en) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit and cd112r blockade |
WO2022044010A1 (en) * | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
US20230374128A1 (en) * | 2020-10-09 | 2023-11-23 | Keio University | Therapeutic agent for immune/inflammatory disease |
CN112341523B (en) * | 2020-11-18 | 2022-09-06 | 上海交通大学医学院 | Small peptide encoded by DLEU2 and application thereof in preparation of immunomodulatory drugs |
CN113209275B (en) * | 2021-03-25 | 2023-01-31 | 大汉生物科技(广东)有限公司 | Application of STCH in preparation of functional product for resisting flavivirus infection |
TW202304965A (en) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof |
EP4377350A2 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Methods and compositions for treating cancer |
CA3231320A1 (en) | 2021-09-15 | 2023-03-23 | Zhiliang CAO | Protein specifically binding to pd-1 and pharmaceutical use thereof |
CA3231553A1 (en) | 2021-09-15 | 2023-03-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
AU2023236289A1 (en) | 2022-03-15 | 2024-08-15 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024159138A1 (en) * | 2023-01-27 | 2024-08-02 | Gentibio, Inc. | Engineered repair regulatory t cells |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050169913A1 (en) * | 1997-05-15 | 2005-08-04 | Trillium Therapeutics Inc. | Compositions comprising antibodies to human FgI2 |
US20080003199A1 (en) * | 2006-05-04 | 2008-01-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
US20100298418A1 (en) * | 2009-05-20 | 2010-11-25 | Veritas Therapeutics Inc. | Assay for measuring plasma FGL-2 and methods and uses thereof |
WO2012031008A2 (en) * | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
US20130251720A1 (en) * | 2008-04-09 | 2013-09-26 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4747825A (en) | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4948592A (en) | 1986-05-09 | 1990-08-14 | Alza Corporation | Pulsed drug delivery |
US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4965251A (en) | 1987-04-03 | 1990-10-23 | The Board Of Regents Of The University Of Washington | Pulse treatment of hemoglobinopathies with erythropoietin |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
ATE318832T1 (en) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | METHOD FOR USING NUCLEIC ACID LIGANDS |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5403590A (en) | 1992-12-21 | 1995-04-04 | New England Deaconess Hospital Corporation | Method of pulsatile drug infusion |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
CA2477312C (en) | 2002-03-01 | 2013-02-26 | Trillium Therapeutics Inc. | Use of soluble fgl2 as an immunosuppressant |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
LT3021869T (en) * | 2013-07-16 | 2020-10-12 | F. Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
-
2015
- 2015-03-20 US US15/127,983 patent/US20170107300A1/en not_active Abandoned
- 2015-03-20 WO PCT/US2015/021784 patent/WO2015143343A2/en active Application Filing
- 2015-03-20 EP EP15765469.0A patent/EP3119913B1/en active Active
-
2018
- 2018-10-02 US US16/149,589 patent/US20190040154A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050169913A1 (en) * | 1997-05-15 | 2005-08-04 | Trillium Therapeutics Inc. | Compositions comprising antibodies to human FgI2 |
US20080003199A1 (en) * | 2006-05-04 | 2008-01-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
US20130251720A1 (en) * | 2008-04-09 | 2013-09-26 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
US20100298418A1 (en) * | 2009-05-20 | 2010-11-25 | Veritas Therapeutics Inc. | Assay for measuring plasma FGL-2 and methods and uses thereof |
WO2012031008A2 (en) * | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
Non-Patent Citations (5)
Title |
---|
FOERSTER ET AL.: "The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection", J HEPATOL., vol. 53, 17 June 2010 (2010-06-17), pages 608 - 615, XP027241346 * |
JOLLER ET AL.: "Cutting edge: TIGIT has T cell -intrinsic inhibitory functions", J IMMUNOL., vol. 186, 1 February 2011 (2011-02-01), pages 1338 - 1342, XP055319470 * |
JOLLER ET AL.: "Immune checkpoints in central nervous system autoimmunity", IMMUNOL REV., vol. 248, 1 July 2012 (2012-07-01), pages 122 - 139, XP055145273 * |
KHATTAR ET AL.: "Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE", PLOS ONE, vol. 8, 11 October 2013 (2013-10-11), pages 1 - 11, XP055358672 * |
YU ET AL., NAT IMMUNOL., vol. 10, 16 November 2008 (2008-11-16), pages 48 - 57, XP055273979 * |
Also Published As
Publication number | Publication date |
---|---|
US20170107300A1 (en) | 2017-04-20 |
EP3119913B1 (en) | 2021-01-06 |
WO2015143343A2 (en) | 2015-09-24 |
EP3119913A4 (en) | 2017-08-16 |
US20190040154A1 (en) | 2019-02-07 |
EP3119913A2 (en) | 2017-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015143343A3 (en) | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring | |
EP3668497A4 (en) | Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response | |
PH12018500057A1 (en) | Substituted oxopyridine derivatives | |
MX2019015311A (en) | Cannabidiolic acid esters compositions and uses thereof. | |
WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
EP4275705A3 (en) | Pancreatitis treatment | |
WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2016210384A3 (en) | Bacteria engineered to treat metabolic diseases | |
WO2015185875A3 (en) | Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory t lymphocytes | |
WO2014151456A3 (en) | Treatment of inflammatory diseases | |
EP3712264A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
EP3310375A4 (en) | Use of low molecular weight fractions of human serum albumin in treating diseases | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
WO2015136287A3 (en) | Compositions and methods relating to the treatment of diseases | |
MX2022010954A (en) | Device for detecting misfolded proteins and methods of use therof. | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
WO2017143115A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
MX2021007116A (en) | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer. | |
EP4342544A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
WO2015123493A3 (en) | Compositions and methods for modulatuion of immune response | |
WO2016081733A3 (en) | Compositions and methods for modulating at2r activity | |
WO2015095789A3 (en) | Suppression of allergic lung inflammation and hyperreactivity | |
MX2019014090A (en) | Methods for the treatment of chronic pouchitis. | |
MD20160040A2 (en) | Pidotimod for use in the treatment of inflammation-associated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15765469 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15127983 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2015765469 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015765469 Country of ref document: EP |